Anteris Technologies is a structural heart company focused on developing innovative & durable health solutions.
Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States.
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis. The company was founded in 2018 and is based in Solana Beach, California, United States.
Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS).
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets.
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.
Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and an efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. They also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Crossover Health designs and delivers a unique and comprehensive employee care experience for companies that understand the financial and cultural return of a healthy, motivated workforce. The company is a primary care medical group that combines advanced health management services and exceptional member experiences within their employee health offering. Crossover Health was founded in 2010 by Scott Shreeve and is based in San Clemente, California.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States.
Private Equity Round in 2020
Prometheus Biosciences, formerly known as Prometheus Laboratories, is a biotechnology company focused on developing and commercializing innovative pharmaceutical and diagnostic products, primarily for gastrointestinal diseases such as inflammatory bowel disease (IBD). Based in San Diego, California, the company offers a range of diagnostic tests, including Anser IFX, Anser ADA, and IBD sgi Diagnostic, which enable healthcare providers to monitor treatment and optimize patient care. Prometheus also markets therapeutic agents, such as Entocort EC and Imuran, for managing conditions like Crohn's disease and rheumatoid arthritis. Additionally, it provides genetic and serologic testing for celiac disease and lactose intolerance, among other disorders. With a commitment to precision medicine, Prometheus aims to enhance individualized patient care through its advanced diagnostic capabilities and therapeutic solutions. The company was founded in 1995 and operates as a subsidiary of Precision IBD, Inc.
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology. It engages in treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .
Private Equity Round in 2020
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.
Pear Therapeutics is a provider of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective services for payors.
Genome Medical is a national telegenomics technology, services, and strategy company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and an efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. They also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. The company was founded in 2009 and is based in Mountain View, California.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
Quellis Biosciences is dedicated to improving the lives of patients suffering from serious rare diseases by developing next-generation antibody therapies that deliver value by improving patient outcomes.Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options.
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types.
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
Vapotherm is specializing in the development, manufacture, and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs, and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification. Vapotherm high velocity therapy has been shown to provide proven, comfortable respiratory support without the use of a mask. High Velocity Therapy is a method of rethinking ventilatory support while keeping patient comfort and compliance in mind.
Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.
Counsyl is a health technology company that offers DNA screening for men, women and their children. Our philosophy is simple - focus on diseases where advanced knowledge makes a difference in health outcomes, whether it's changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead. Counsyl has screened over 500,000 patients and served over 6,000 health professionals in its modern clinical laboratory. From the purely mechanical to profoundly human, Counsyl strives to make DNA screening truly accessible to everyone. The team consists of world class engineers, scientists and clinical experts as well as a renowned engineering and scientific advisory board. Counsyl integrates sophisticated technology with custom robotic automation in its accredited medical laboratory. This focus on technology has made Counsyl a leader in helping patients and doctors communicate about medical results in real time. Its products have won the Wall Street Journal’s Innovation Award for Medicine, and have been named one of Scientific American's "Top 10 World Changing Ideas." Counsyl’s Family Prep Screen has already helped hundreds of thousands of people discover critical information before having children, and the Counsyl platform now extends beyond family preparation to include informed pregnancy and cancer screening.
Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.The company's therapeutics are novel, locally-acting small molecules targeting inflammatory bowel disease (IBD), crohn's disease (CD) and ulcerative colitis (UC), enabling healthcare providers to cure their patients.
Vapotherm is specializing in the development, manufacture, and marketing of respiratory devices that improve clinical outcomes, reduce overall delivery costs, and improve quality of life for patients. The company's breakthrough technology centers on the benefits of high flow delivery of breathing gases through a patented process for heating and humidification. Vapotherm high velocity therapy has been shown to provide proven, comfortable respiratory support without the use of a mask. High Velocity Therapy is a method of rethinking ventilatory support while keeping patient comfort and compliance in mind.
Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with the founding scientists and entrepreneurs of new ventures to support their vision while allowing a more efficient development model to benefit company founders and early equity holders.
Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.
Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases. Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization. It was founded in 2004 and headquartered in Vancouver, British Columbia.
Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.
Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial.
Alliqua is a biomedical company focused on the development, manufacturing, and marketing of its own proprietary products, utilizing its existing technology portfolio. The company currently markets its own proprietary brands of wound dressings such as SilverSeal® Hydrogel, an antimicrobial dressing; and Hydress® a moist wound dressing. The company intends to pursue projects in the fields of the active ingredient and transdermal drug delivery, as well as advanced wound care. Alliqua’s core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin.
Champions Oncology was founded by some of the world’s most renowned specialists in the field of cancer diagnosis, treatment, and research. Our team is comprised of seasoned oncology professionals passionately dedicated to working with you to accelerate oncology drug development, improve outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar model for growing and testing human tumors.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells.